The Relationship Between Re-Endothelialization and Endothelial Function After DES Implantation: Comparison Between Paclitaxel Eluting Stent and Zotarolimus Eluting Stent

Suguru Murase, MD, Yoriyasu Suzuki, MD, Toshikazu Yamaguchi, CE, Osamu Matsuda, MD, Akira Murata, MD, and Tatsuya Ito, MD

Background: Several studies have reported re-endothelialization and endothelial function after drug-eluting stent (DES) implantation; however, the relationship between re-endothelialization and endothelial function after DES implantation has not been investigated yet.

Methods: A total of 14 patients underwent evaluation of re-endothelialization by optical coherence tomography (OCT) and endothelial function by incremental Ach infusion at 9 months after DES implantation (ZES: N = 7, PES: N = 7). The neointimal thickness (NIT) inside each strut, strut coverage, and malapposition at every 1 mm cross-section were evaluated by OCT and the endothelial function was estimated by measuring the coronary vaso-reactivity in response to acetylcholine (Ach) infusion into coronary arteries. Results: Zotarolimus eluting stent (ZES), compared with paclitaxel eluting stent (PES), showed more homogeneous neointimal coverage of stent struts and low rate of malapposition. Vasoconstriction in response to Ach in the peri-stent region was also less pronounced in ZES than PES. In particular, vasoconstriction was more often observed in cases with inhomogeneous neointimal coverage of stent struts in the PES group. Conclusions: Our findings suggest that endothelial function seems to be better preserved with ZES than PES, and homogeneous neointimal coverage of stent struts seem to be associated with the preserved endothelial function.

Key words: re-endothelialization; endothelial function; TAXUS; endeavor

INTRODUCTION

Recent reports have raised concerns that drug-eluting stent (DES) implantation may cause delayed or absent endothelialization of traumatized coronary vessel walls that could result in coronary endothelial dysfunction [1,2]. A recent human autopsy study showed that the most important histological and morphometric predictors of late stent thrombosis (LST) were endothelial coverage and the ratio of incomplete neointimal coverage of stent struts after DES implantation [3].

In a series of 8,000 DESs, Daemen et al. reported a consistent 0.6% LST rate over the first 3 years post-stenting [4]. LST is a various factorial phenomenon [5]; however, one significant factor is failure of stent strut re-endothelialization [6].

A zotarolimus-eluting stent (ZES) (Endeavor, Medtronic CardioVascular, Santa Rosa, CA), a cobalt chromium-based thin-strut stent with a phosphorylcholine biocompatible polymer and a shorter drug-elution time of within 2 weeks, have been developed as a second-generation DES and is reported to promote rapid and uniform healing of the endothelium [7]. It has been shown to have a significantly lower prevalence of uncovered struts and malapposed struts than a sirolimus-eluting stent (SES) or a paclitaxel-eluting
stent (PES), called “first-generation DES” at more than 12 months follow-up on optical coherence tomography (OCT) [8].

However, it is not clear whether neointimal strut coverage detected by OCT can be used as a surrogate for vessel healing after DES implantation.

Changes in coronary endothelial function may be important prognostic factors in the long-term clinical outcomes of patients after DES implantation. In this study, we evaluated the relationship between neointimal strut coverage or malapposition detected by OCT and coronary vasomotion in response to acetylcholine at 9 months after ZES implantation.

METHODS

Study Design and Samples
The baseline clinical characteristics are summarized in Table I. A total of 14 patients who were diagnosed with stable angina and were treated with a single stent (ZES: N = 7, PES: N = 7) for a de novo single lesion in the coronary arteries. Eligible subjects were older than 20 years of age, with stable or unstable coronary syndromes. Exclusion criteria were left main disease, ongoing/recent myocardial infarction, previous target vessel stenting, creatinine >2.0 mg/dl, ejection fraction <30%, no suitable anatomy for OCT (ostial lesions and extreme tortuosity). Dual antiplatelet therapy with aspirin and clopidogrel was maintained for 9 months to follow. For all procedures, IVUS-guided stenting was performed. Stenting was performed up to full stent-vessel wall apposition.

Evaluation of Endothelial Function
At 9-month follow-up, endothelial function was estimated by measuring the coronary vasoreactivity in response to Ach infusion into the coronary arteries (Ach1: 20 μg; Ach2: 50 μg; Ach3: 100 μg for 1 min, performed at an infusion rate of 5 ml/min); a 5-min interval was allowed between doses (Fig. 1). When the maximum dose was reached, an intracoronary bolus injection of nitroglycerin (200 μg) was administered. Fujii et al. reported changes in vasomotor reaction 3 months after ZES implantation [9]. It changed over 25% in mean vessel diameter at distal segment after intracoronary infusion of acetylcholine with incremental dose of 100 μg, therefore we defined spasm as % change of vasoreactivity at stent distal position >25% by angiography, and we measured neointimal hyperplasia thickness on each strut between two groups having spasm or not.

Evaluation of Re-Endothelialization by OCT
After evaluation of endothelial function, OCT was performed to assess the re-endothelialization after DES implantation. The OCT images were obtained with the M2 OCT imaging system (LightLab Imaging, Westford, MA). Motorized pullback OCT imaging was performed at a pullback rate of 1.0 mm/sec. Images were acquired at 15 frames/sec, displayed with a color look-up table and digitally archived. The OCT measurements were performed with LightLab OCT imaging proprietary software with a mouse-based Interface. The neointimal thickness (NIT) inside each strut, strut coverage, and malapposition at every 1 mm cross-section were evaluated. We defined as follows: uncovered slice: three continuous uncovered stent struts were observed in the same slice (Fig. 2) [10].

Statistical Analysis
All statistical analyses were performed using statistical package for the social sciences (SPSS) ver.20 (SPSS, Chicago, IL). Quantitative data were expressed as mean ± standard deviation and were analyzed by student’s t-test. A two-tailed P of <0.05 was considered statistically significant.

RESULTS
The baseline clinical characteristics are summarized in Table I. Although DES were not randomly selected, baseline characteristics were similar between two stent
groups. In the PES group, the prevalence of diabetes and dyslipidemia, and the average age was higher than ZES group. In addition, ZES group was all male. However, the mean stent diameter and stent length was similar between the two groups.

Comparison of vasoreactivity between ZES and PES is summarized in Fig. 3. The incidence of acetylcholine-induced spasm was higher in the PES group, also if a proximal portion and a distal portion compared with ZES group.

Strut-based evaluation of re-endothelialization by OCT is summarized in Table II. The ZES group demonstrated a significantly greater magnitude of neointimal coverage than the PES group (0.27 ± 0.14 mm vs. 0.17 ± 0.18 mm, \( P < 0.01 \)), and a low rate of malapposition (0 vs. 2.7%, \( P < 0.01 \)). The ZES group also

---

**Fig. 1.** Coronary vasoreactivity in response to Ach infusion into coronary arteries. Left, the first imaging without nitroglycerine. Center, imaging after acetylcholine injected. Right, imaging after nitroglycerine injected. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

**Fig. 2.** Stent struts classification by intracoronary optical coherence tomography: type 1-malapposed/uncovered strut, type 2-protuding/uncovered strut, and type 3/4-embedded strut. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
showed a lower neointima-free frame ratio than did the PES group.

Spasm was defined as percent change of vasoreactivity at distal position >25% of the stent as described above. Vasoconstriction in response to ACh in the peristent region was also less pronounced in the ZES than PES (28.6 vs. 57.1%, P < 0.01). In the spasm group, there was a lower and inhomogeneous neointimal coverage than in the nonspasm group (0.21 ± 0.19 mm vs. 0.25 ± 0.14 mm, P < 0.01). In particular, vasoconstriction was more often observed in cases with inhomogeneous neointimal coverage of stent struts in the PES group.

DISCUSSION

This is the first study for Japanese to evaluate the association between re-endothelialization and endothelial function by acetylcholine infusion at 9 months after ZES implantation. This study demonstrated that the degree of vasoconstriction in response to acetylcholine was associated with the number of uncovered struts and malapposition detected by OCT.

Although intrastent thrombosis is rare, it has an extremely serious prognosis and a reported mortality reaching 45% [11]. Noncoverage strut is one causal factor of intrastent thrombosis, especially in cases of resistance to or premature discontinuation of dual antiplatelet therapy. A recent autopsy study showed that the most important histological and morphometric predictors of LST were endothelial coverage and the ratio of uncovered to total stent struts after DES implantation [3,12]. Ko et al., previous OCT studies in patients with DES-related very late stent thrombosis (VLST), reported that in 15.8% of patients were uncovered stent struts observed [13]. Therefore, identification of neointima over stent struts could provide important information to predict LST. There is, however, a lack of instruments for the in vivo study of re-endothelialization. Under these circumstances, OCT would seem to be most reliable, providing precise, reproducible, strut-by-strut measurements [14]. However, it is not quite clear to whether complete neointimal coverage of stent struts can be established as a surrogate for vessel healing after implantation of DES.

The vascular endothelium plays a critical role in the regulation of arterial function through the synthesis and elaboration of a number of antiatherogenic factors such as nitric oxide (NO). Acetylcholine evokes a NO-mediated vasodilatory response in healthy arteries via muscarinic endothelial membrane receptors, but this effect is blunted, and paradoxical vasoconstriction is observed with endothelial dysfunction [15]. Therefore, coronary angiography after intracoronary acetylcholine infusion is one of the most used methods for evaluating coronary endothelial function after DES implantation. In our study, neointimal coverage was not complete with significant difference in the spasm group.

A histopathological study showed that re-endothelialisation was complete 3 months after bare-metal stent (BMS) implantation [16]. However, there is some report of abnormal coronary vasoconstrictive responses with acetylcholine after implanted first...

**TABLE II. Angiographic and OCT Analysis**

|                          | ZES (n = 7) | PES (n = 7) | P-value |
|--------------------------|------------|------------|---------|
| Spasm (+) (%)            | 28.6       | 57.1       |         |
| Strut-based analysis     | n = 1590   | n = 897    | <0.0001 |
| Coverage (%)             |            |            |         |
| 1/2                      | 0          | 13.4       |         |
| 3/4                      | 100        | 86.6       |         |
| Malapposition (%)        | 0          | 2.7        | <0.0001 |
| NIT (mm)                 | 0.27 ± 0.14| 0.17 ± 0.18| <0.0001 |
|                          | Spasm (+)  | Spasm (-)  |         |
| Coverage (%)             |            |            | <0.0001 |
| 1/2                      | 11.1       | 1.3        |         |
| 3/4                      | 88.9       | 98.7       |         |
| Malapposition (%)        | 2.7        | 0          | <0.0001 |
| NIT (mm)                 | 0.21 ± 0.19| 0.25 ± 0.14| <0.0001 |

Evaluation of re-endothelialization by OCT. Spasm was defined as %change of vasoreactivity at stent distal position >25%. Values are given as mean ± SD, or n (%).

NIT, neointimal thickness; OCT, optical coherence tomography; ZES, zotarolimus eluting stent; PES, paclitaxel stent.

Catheterization and Cardiovascular Interventions DOI 10.1002/ccd. Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
generation DES [17]. It has been reported that inhibition of smooth muscle cell of proliferation and endothelial regeneration [18], and local coronary inflammation caused delayed re-endothelialisation of stent and vessel walls [19]. These findings suggest that the coverage of stent struts with neointimal hyperplasia may offer protective advantage for early vessel healing.

Our data show greater neointimal hyperplasia at 9 months in the ZES group (0.27 vs. 0.17 mm in the PES group). This value is not inferior to previous angiographic findings based on late loss. Pocock et al., in 11 randomized trials, reported between 0.60 and 0.61 mm late loss with ZES and 0.30–0.49 mm with PES at 1 year [20].

In the literature, significantly less endothelial strut coverage was more apparent with earlier stent designs of Sirolimus eluting stent (SES) or PES relative to the more recent ZES [21]. It is considered that the drug dose/polymer combination and release properties may also affect endothelial cell proliferation and migration. However, seven randomized trials demonstrated that ZES showed more in-stent restenosis, late lumen loss “in stent” and “in segment” [22]. One should be careful with the implantation of small size ZES; but conversely, it will be convenient when obliged to discontinue dual antiplatelet therapy.

However, noncoverage struts could not be a sufficient condition of the development LST, because there was a significant difference between the rate of deficient coverage in vivo on OCT and the rate of LST. A randomized controlled trial has reported that the rate of incident LST after ZES was 0.9% at the 5-year follow-up [23]. It may be a determining risk factor such as malapposed stent struts, rupture of lipid-laden neointima inside the DESs, or premature discontinuation of antiplatelet therapy. These remarks lead us to continue dual antiplatelet therapy beyond the first 6 months after DES implantation in patients who do not have a high risk of hemorrhage, in line with the latest report [24].

Our present study showed OCT to be an eligible safety tool for investigation re-endothelialization and partial strut coverage. Some randomized comparative OCT trials may provide prognostic factors with the resolution of poststenting healing and may help to determine the term of dual antiplatelet therapy in the future.

STUDY LIMITATIONS

There were three major limitations of this study. First, this study was not a prospective, randomized, controlled study. Secondly, no baseline OCT data were available. Because this is a clinical retrospective study, we cannot show the vasoreactivity in the reference vessel on account of the insurance. Finally, this study was a single-center study with relatively small population and might have a risk of selection bias, therefore baseline patient characteristics becomes the huge difference in one difference. There are huge differences in gender, age, and risk factors of diabetes and dyslipidemia, but it is a limit to exclude significant difference because of small sample size. There is a possibility that higher severity patient in the PES group, but QCA data has no significant difference between two stent groups. However, we evaluated about 1000 stent struts and it seems to be enough to evaluate the relationship between neointimal strut coverage and coronary vasomotion.

CONCLUSION

Our findings suggest that endothelial function can be better preserved in association with ZES than PES and homogeneous neointimal coverage of stent struts can be associated with the preserved endothelial function.

It is conceivable that the second-generation DES, “ZES” could be more beneficial under specific clinical conditions, such as large vessels, patients who cannot continue dual antiplatelet therapy for a certain reason.

REFERENCES

1. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Long-term (>2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: Comparison to 9-month follow-up results. Int J Cardiovasc Imaging 2011;27:875–881.
2. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583–591.
3. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007;115:2435–2441.
4. Daemen J, Wennaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369:667–678.
5. Holmes DR Jr, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: An objective appraisal. J Am Coll Cardiol 2007;50:109–118.
6. Awata M, Kotani J, Uematsu M, et al. Serial angiographic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: Comparison with bare-metal stents. Circulation 2007;116:910–916.
7. Whelan DM, van der Giessen WJ, Krabbenbom SC, van Vliet EA, Verdouw PD, Serruys PW, van Beusekom HM. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000;83:338–345.
8. Li S, Wang Y, Gai L, Yang T, Liu H, Wang Z, Bai Q, Xu X, Chen Y. Evaluation of neointimal coverage and apposition with various drug-eluting stents over 12 months after implantation by optical coherence tomography. Int J Cardiol 2013;162:166–171.
9. Fujii K, Kawasaki D, Oka K, et al. Endothelium-dependent coronary vasomotor response and neointimal coverage of
zotarolimus-eluting stents 3 months after implantation. Heart 2011;97:977–982.

10. Guagliumi G, Sirbu V. Optical coherence tomography: High resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008;72:237–247.

11. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126–2130.

12. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193–202.

13. Ko YG, Kim DM, Cho JM, Choi SY, Yoon JH, Kim JS, Kim BK, Choi D, Jang Y, Hong MK. Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. Int J Cardiovasc Imaging 2012;28:715–723.

14. Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, Fearon WF. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv 2008;1:168–173.

15. Kasprzak JD, Klosinska M, Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacol Rep 2006;58 (Suppl): 33–40.

16. Grewe PH, Denke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157–165.

17. Kim JW, Suh SY, Choi CU, Na JO, Kim EJ, Rha SW, Park CG, Seo HS, Oh DJ. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. JACC Cardiovasc Interv 2008;1:65–71.

18. Mohaci PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484–492.

19. Yoneda S, Abe S, Kanaya T, et al. Late-phase inflammatory response as a feature on in-stent restenosis after drug-eluting stent implantation. Coron Artery Dis 2013;24:368–373.

20. Pocock SJ, Lansky AJ, Mehran R, et al. Angiographic surrogate end points in drug-eluting stent trials: A systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008;51:23–32.

21. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333–342.

22. Sethi A, Bahekar A, Bhuriya R, Bajaj A, Singh PP, Arora R, Khosla S. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: A meta-analysis of randomized trials. Arch Cardiovasc Dis 2012;105:544–556.

23. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the medtronic endeavor drug [ABT-578] eluting coronary stent system versus the cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 2011;4:543–550.

24. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–513.